News | December 24, 2025
Niagen Bioscience secures full ownership of key NAD+ patents in major IP move
The portfolio includes foundational patents on the production, composition, and commercial use of NR
The portfolio includes foundational patents on the production, composition, and commercial use of NR
AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life
Shonan iPark was chosen for its globally connected life-science ecosystem, which unites pharmaceutical firms, next-generation medicine developers, AI and digital health innovators, venture capital, and academia
NUFYMCO BLA has been approved by the USFDA
Wegovy pill showed a mean weight loss of 16.6% in the OASIS 4 trial
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
Subscribe To Our Newsletter & Stay Updated
